Efficacy of Demethylated Drugs Combined with Low-Dose Cytarabine in the Treatment of Refractory Recurrent Acute Myeloid Leukemia
Objective To delve into the efficacy and safety of demethylated drugs combined with low dose cytarabine in the treatment of refractory recurrent acute myeloid leukemia(AML).Methods Eighty-five cases with refractory relapsed AML admitted and diagnosed in Puyang City Anyang District Hospital from October 2017 to October 2022 were randomly divided into control group(42 cases)and observation group(43 cases).The control group received standard CAG regimen(acclarithromycin,cytarabine and recombinant human granulocyte colony-stimulating factor).The observation group received azacitidine/decitabine and small dose of cytarabine.The clinical efficacy,prognosis and survival,changes in hematological indexes[white blood cell count(WBC),platelet count(PLT),hemoglobin(HGB)]before and after treatment,and adverse reactions were compared in two groups.Results Compared with control group,the total remission rate of observation group(72.09％)was higher(45.24％)(P＜0.05).Compared with control group,the 6-month survival rate in the observation group was higher(P＜0.05).After treatment,the levels of WBC,PLT and HGB in two groups were higher than before treatment(P＜0.05).After treatment,compared with control group,the levels of WBC,PLT and HGB in observation group were higher(P＜0.05).The incidence of adverse reaction between two groups was no differences(P＞0.05).Conclusion Demethylated drugs combined with low-dose cytarabine for refractory relapsed AML cases have definite clinical efficacy,can prolong the survival time of patients,improve hematological indexes,and have good safety and clinical application value.
万方数据
维普
